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Cardiovascular disease contributes greatly to the disease burden in many developed countries. 
Cardiovascular magnetic resonance (CMR) is a powerful imaging modality that can diagnose 
a vast range of these diseases. When combined with an extracellular contrast agent, CMR can 
not only diagnose the function and size of the heart but also provide detailed information on 
the myocardial tissue. CMR T1 and extracellular volume (ECV) mapping can be used to 
quantitatively characterise the tissue properties of the myocardium. The main objective of this 
work was to determine how to use these and other imaging capabilities of CMR imaging in 
order to maximise the diagnostic abilities and predict adverse outcomes. 
Study I examined whether T1 and ECV mapping could be useful for detecting myocarditis 
when acquired early after contrast administration. Study II looked at the prevalence of 
diffusely increased ECV in a clinical population. Study III presents a novel way of calculating 
global wall thickness (GT), i e the average thickness of the whole left ventricle. GT can easily 
be calculated from the left ventricular mass and volume which are measured as a part of a 
normal CMR examination. Study IV examined the feasibility of determining the myocardial 
cell size using early T1 mapping and calculating the intra-cellular lifetime of water (tau). 
Study I found no benefit of performing early compared to late post-contrast imaging when 
detecting myocarditis. Study II found that found that 8 % of a clinical population had 
diffusely increased ECV, that increased ECV was more common in patients with a dilated 
left ventricle and that focal lesions were more common in patients with decreased systolic 
function. Study III derived and validated a new measure for global wall thickness (GT) that 
can be easily calculated from the left ventricular mass (LVM) and volume. GT was highly 
prognostic in patients with otherwise normal findings and can be used together with LVM to 
classify different types of hypertrophy. Study IV found that measuring the size of 
cardiomyocytes using contrast-enhanced CMR in a clinical setting was not reliable using the 
slow exchange model of transcytolemmal water exchange. 
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1 CARDIAC MAGNETIC RESONANCE IMAGING 
1.1 MAGNETIC RESONANCE IMAGING (MRI) 
Magnetic resonance imaging (MRI) is an imaging methodology based on the nuclear 
magnetic resonance (NMR) method. Spin is a form of angular momentum in atomic nuclei 
and other particles. Both neutrons and protons have non-zero spin and NMR is only feasible 
on isotopes that have an odd number of neutrons and/or protons. Particles with non-zero spin 
also have a non-zero magnetic dipole moment. When this magnetic dipole moment is 
exposed to an external magnetic field, its corresponding angular momentum vector will start 
rotating, a process called precession. The angular momentum vector will precess at the 
Larmor frequency f, which is determined by the gyromagnetic ratio γ and the magnetic field 
strength B as. 
! = #
$%
&   (Equation 1) 
When considering an ensemble of many particles exposed to a magnetic field, the particles’ 
angular momentum vectors will start to precess and they will have a slight tendency to 
precess around an axle parallel to the magnetic field causing slightly more magnetisation in 
this direction. It is this small net magnetisation vector that makes MRI possible (1). 
The magnetic field strength is measured in Tesla (T) and the most commonly used field 
strengths of MRI scanners in clinical settings are 1.5 T and 3 T. Higher field strengths will 
have larger net magnetisation vectors but higher field strength is not always desirable, not 
least due to cost. 
In medical imaging, hydrogen is the most commonly imaged isotope due to its abundance in 
the body as part of water molecules. For hydrogen the gyromagnetic ratio γ/(2π) is 
approximately 42.6 MHz/T and from Equation 1 follows that the Larmor frequency for 
hydrogen is 64 MHz and 128 MHz at 1.5 T and 3 T respectively. Since these frequencies are 
close to the commercial radio frequency band (88–108 MHz), shielding the MRI scanner 
from outside interference is essential. 
1.2 T1 AND T2 
The precession in the magnetic field does not generate any signal in its equilibrium state 
unless there is a disturbance. This disturbance is caused by the radio frequency (RF) 
transmitter coils of the scanner emitting RF pulses tuned to Larmor frequency. The RF pulse 
needs to be perpendicular to the magnetic field and generates both an electrical field and a 
magnetic field. When trying to adapt to the new magnetic field, the net magnetisation vector 
deviates from its equilibrium position. 
Following the RF pulse, the net magnetisation vector will return to its original state. During 
this process, further RF pulses can be applied in order to perform a readout. The readout 
pulse turns the net magnetisation vector slightly, and this generates a signal perpendicular to 
 
2 
the magnetic field during this readout phase that can be detected by RF receiver coils tuned to 
the same frequency as the transmitter coils. Since the signal is comparatively weak, these 
coils need to be placed in close proximity to the imaged object, which often means being 
placed close to the patient’s body. 
The return to the equilibrium state is described by two time constants: T1 or spin-lattice 
relaxation time, and T2 or spin-spin relaxation time. T2 describes how long time it takes for 
the magnetisation to disperse in the horizontal plane (xy-plane) perpendicular to the magnetic 
field (in the z-direction), and T1 how long time it takes for the signal to recover in the (z) 
direction of the magnetic field. These recoveries are described by the following two equations 
and figures: 
'( = ')(1 − -
. /01)   (Equation 2) 
'34 = ')	-
. /06   (Equation 3) 
 
Figure 1. T1 relaxation 
This figure shows an example of T1 relaxation with the signal recovering in the 
(z) direction of the magnetic field at a rate determined by T1 as described in 






Figure 2. T2 relaxation 
This figure shows an example of T2 relaxation with the signal disappearing in the 
(xy) plane, perpendicular to the magnetic field at a rate determined by T2 as 
described in Equation 3. In this example T2 is 50 ms which is a normal value for 
T2 in myocardium. 
1.3 T1 MAPPING 
Early work on T1 measurement was performed by Look and Locker in the late 1960’s for 
application in nuclear magnetic resonance spectroscopy (2,3). It took several decades before a 
T1 mapping could be applied clinically in CMR, and this sequence was called the modified 
Look-Locker inversion recovery (MOLLI) sequence (4), which was found to provide 
reproducible T1 values (5). In MOLLI, the magnetisation is flipped 180º and the return to the 
original state, which is governed by T1, is measured by exposing the recovering signal for 
small disturbances, flipping the signal by a certain number of degrees in order to obtain a 
signal in the xy-plane that is measurable. 
An issue when doing an inversion (180° pulse) followed by successive readouts is that the 
signal will be affected by the readouts. This means that T1* is measured and not the actual T1. 
Consequently, T1 has to be obtained using a correction factor which is only valid for small 
flip angles (6) and inadequate correction can cause errors. The difference between the 





Figure 3. T1 relaxation with and without readouts. 
This figure shows T1 relaxation which is affected by readouts every second (blue 
solid line) and T1 relaxation that is not affected but any readouts (dashed red 
line). In this example T1 is again set to 1 s for both curves. 
The original MOLLI sequence used three inversions followed by read-outs at end diastole in 
the following pattern: first inversion followed by three read-outs, (and three heartbeats 
pause); second inversion followed by three read-outs (and three heartbeats pause); third 
inversion followed by five readouts (4). This original MOLLI was therefore called 3(3)3(3)5, 
and encompassed 17 heartbeats in total. The pauses are needed for full relaxation, normally 5 
times T1 is considered enough to allow for adequate relaxation, but this has to be increased to 
even longer times when readouts are performed, as evident in Figure 3. 
Although the original 17 heartbeat MOLLI could be performed within one breath-hold, some 
patients would struggle with such a duration of breath-hold. This was later shortened to two 
inversions and eleven heartbeats 3(3)5 (7) which was found to give similar results for T1 (8) 
and changed to 5(3)3 in order to reduce heart rate dependency (9). Three inversions but fewer 
readouts in the form om 4(1)3(1)2 was found to be superior for lower values of T1 which 
occur post-contrast. The latter two MOLLI-versions were later modified to count seconds 
instead of heartbeats, i e readouts during at least five seconds followed by at least three 
seconds pause, etc, in order to make time for sufficient signal relaxation. These versions were 
called 5s(3s)3s and 4s(1s)3s(1s)2s and only differ for heartrates above 60 beats per minute. 
Other versions of T1 mapping have also been described. One of these is called Shortened 
MOLLI (ShMOLLI) which only uses 9 heartbeats 5(1)1(1)1 and is less heartrate dependent 
than the original MOLLI (10). An alternative to performing T1 mapping using inversion 
recovery is to use saturation recovery such as SAturation recovery Single Shot Acquisition 
(SASHA) (11). SASHA saturates the signal with the benefit that for each readout, the readout 
does not affect future readouts in the way that happens with MOLLI. However, the drawback 
with SASHA is that the dynamic range is half as large (0 to 1 instead of -1 to 1 for MOLLI). 
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This results in SASHA having a better accuracy but worse precision compared to MOLLI 
(12), i e on average the results will be more correct but the variability will be higher. The 
studies that form part of this thesis mainly use the 5(3)3 version of MOLLI for both pre- and 
post-contrast T1 mapping. 
1.4 ECV MAPPING 
The inverse of T1 is called the relaxation rate, R1, and the difference in R1 between post- and 
pre-contrast images is called ∆R1, which is proportional to the concentration of contrast agent, 





= D7,			EFGH.IFJHKLGH − D7,			EKM.IFJHKLGHN =
∆D7~contrast	agent	concentration   (Equation 4) 
Since ∆R1 is proportional to contrast agent concentration, the contrast agent’s partition 
coefficient λ between the tissue and the blood pool can be calculated from T1 measured in the 




   (Equation 5)	
If the contrast agent is extracellular in its biodistribution, which most contrast agents are, the 
extracellular volume (ECV) fraction of the myocardium can be calculated if the ECV of 
blood is known. In a centrifuged blood sample, the red blood cells (erythrocytes) will end up 
at the bottom of the tube and their proportion of the sample is called haematocrit (hct) or 
erythrocyte volume fraction (EVF). The ECV of the blood sample is therefore the remaining 




   (Equation 6)	
Early work on distribution volumes was performed as early as in the late 1990’s when the 
distribution volume of gadopentetate dimeglumine was compared to that of 99mTc-DTPA 
using magnetic resonance imaging and autoradiography respectively. These methods were 
found to provide similar results, and the distribution volume was the extracellular space 
which also was found to be increased in reperfused infarction (13). With the advent of T1 
mapping it was not only possible to measure ECV in an area but also on a pixel by pixel basis 
(7), which was additionally made easier by implementing automated motion correction and 
co-registration (14). 
1.5 CONTRAST AGENTS 
To increase the sensitivity of magnetic resonance imaging, contrast agents can be used. These 
can be ferromagnetic, paramagnetic, or superparamagnetic and they affect T1 as well as T2. 
Ferromagnetic contrast agents contain iron and mainly affect T2, while the most commonly 
used contrast agents contain gadolinium (Gd), and gadolinium-based contrast agents (GBCA) 
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mainly affect T1. GBCA are indirect contrast agents since their effect is shortening of the 
relaxation times of the water protons in their immediate vicinity. The water protons’ T1 is 
shortened, and this causes increased signal intensity (15). 
In contrast agents, Gd is always bound to a carrier molecule, or chelate. The dissociated non-
chelated Gd (Gd3+) can be deposited in various parts of the body and have toxic effects at 
concentrations that are rarely achieved clinically (16). The compound structure of GBCA can 
either be linear or macrocyclic where the macrocyclic types tend to be more stable with lower 
risk of dissociation and therefore safer (16). There are both ionic and non-ionic GBCA, where 
the ionic agents tend be more stable (17). In the studies that are part of this thesis, only 
macrocyclic contrast agents were used, both ionic and non-ionic. 
Immediate adverse reactions are rare and serious reactions even more so with 614 reported 
severe reactions in 200 million administrations of GBCA, equating to one severe reaction for 
325 000 exams (17). The effects of GBCA on the foetus or child in pregnant or lactating 
women are poorly known and contrast administration is therefore only performed on a case-
by-case basis according to most guidelines (17). 
In 2006, several cases of nephrogenic systemic fibrosis (NSF) were found in patients with 
end-stage renal disease that were on dialysis and that had undergone MRI with GBCA (18). 
The half-life to renal excretion for GBCA is roughly two hours in patients with normal renal 
function, but this time is greatly increased in patients with severely impaired renal function. 
This gives increased time for the Gd ions to be dissociated from their chelates, form 
complexes in tissue which leads to a response from the immune system which in turn leads to 
fibrosis (17). Macrocyclic GBCA account for less than 1 % of the cases of NSF due to their 
higher stability (17). Early work on contrast-enhanced CMR was done using a gadolinium 
(Gd) molecule coupled with diethylenetriaminepentaacetic acid (DTPA) (19), and the 
versions of GBCA with Gd-DTPA make up the overwhelming majority of NSF cases (17). 
1.6 LATE GADOLINIUM ENHANCEMENT (LGE) 
Late gadolinium enhancement (LGE) is the standard technique for identifying focal lesions in 
the myocardium of both ischemic (20) and non-ischemic (21) origin. The extracellular 
contrast agents distribute into the extracellular space, which will be expanded in the setting of 
myocardial necrosis and fibrosis. The LGE sequence is similar to the MOLLI sequence 
inasmuch both are inversion recovery sequences. The focal areas with an expanded 
extracellular space will have a lower T1 due to the increased relative contrast agent 
concentration, and will therefore recover faster compared to normal tissue (22). When 
performing LGE imaging, an inversion time (TI) needs to bet set while scanning, to null the 




Figure 4. T1 relaxation in LGE 
This figure shows T1 relaxation for healthy myocardium (blue solid line, 
T1 500 ms) and T1 relaxation for focally affected myocardium (dashed red line, 
T1 250 ms), where T1 is shorter due to a higher contrast agent concentration, 
which in turn is a consequence of an enlarged extracellular space. The inversion 
time (TI) has been set so that the healthy myocardium has zero magnetisation, 
which gives no signal, and therefor black pixels in the image, as shown in the 
colour scale bar on the left. At this time point TI, the contrast between the 
affected and healthy myocardium is at its maximum and the focally affected 
myocardium will appear much brighter in the image. 
Herein lies both the strength and the weakness of the method. The strength is that the nulling 
of the signal of healthy myocardium gives a high contrast in the image that easily separates 
focal lesions from healthy myocardium. The drawback is that there is no sure way to tell if 
the healthy myocardium really is healthy. Diffuse changes affecting the whole myocardium 
will not be easily detected using LGE. ECV can detect these diffuse changes, which is the 
topic of Study II. 
LGE has been developed further using phase-sensitive inversion recovery (PSIR), where not 
only the magnitude of the relaxation curve but also its phase (plus or minus) is taken into 
account. This makes the nulling of healthy myocardium less critical (23). 
Since LGE imaging is also based on T1 relaxation, synthetic LGE images (24) can be 
generated from T1 maps, where TI can be optimized during image evaluation after image 





2.1 EXTRACELLULAR VOLUME 
The body can be divided into intra- and extracellular spaces. In the blood pool, the 
extracellular volume (ECV) consists of blood plasma, and in the myocardium, collagen is an 
important part of extracellular space (25). In the myocardium, a normal extracellular volume 
(ECV) fraction is 20–30 %, and a good correlation has been found between ECV 
measurements and the amount of fibrosis (26–28). 
An increase in ECV has been found to be an important risk factor for death and 
hospitalisation for heart failure. A study from 2012 found that ECV, measured in 
myocardium excluding infarctions, was related to short-term mortality (median follow-up 
time 0.8 years), even when adjusting for systolic function and age, and when separately 
analysing patients with and without non-ischemic scars (29). Subsequent studies found that 
an increase in ECV was associated with mortality and/or admission to hospital for heart 
failure during median follow-up times of 1.3 years (30), and 1.7 years (31), respectively. A 
study with biopsy-verified ECV found ECV to be an independent predictor of event-free 
survival (median follow-up time 0.8 years), among imaging parameters but not when clinical 
parameters were included (27). ECV can also be measured without measuring the 
haematocrit and this “synthetic” ECV has also been found to be associated with mortality 
during a median follow-up time of 1.7 years (28). 
2.2 MYOCARDITIS 
Myocarditis is defined as an inflammation of the myocardium. The inflammation is often first 
induced by a viral infection that triggers an immune response which in turn causes damage to 
the tissue (32). 
Myocarditis often occurs in younger adults, and has been shown to be the cause of 12 % of 
sudden death in younger individuals (33). Myocarditis can also cause death and heart failure 
in children, and sometimes heart transplantation is needed. In patients up to 18 years of age, 
myocarditis mostly affects teenagers (about half of the cases) and children below two years of 
age (about a quarter of the cases) (34). 
The symptoms of myocarditis can range from chest pain to acute heart failure and it is 
therefore often difficult to diagnose myocarditis based on clinical information alone. A step 
forward was made with the introduction of the so called Dallas criteria for diagnosing 
myocarditis by endomyocardial biopsy (EMB) where an inflammatory infiltrate has to be 
located next to damaged myocytes in order for the diagnosis to be made (35). However, EMB 
is prone to sampling errors even if several biopsies are made. The problem is made worse by 
the fact that myocarditis often affects the inferolateral epicardial part of the left ventricle, 
whereas only the septum is accessible when biopsies are taken from the right ventricle, which 
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is most often the case. Severe procedural complications can also occur during EMB, and the 
total complication rate has been found to be 6 % (36). 
Echocardiography can be used to evaluate left ventricular size, function, and wall thickness, 
but reliable myocardial tissue characterisation has not made it to clinical mainstream. 
Therefore, there are several reasons for developing new diagnostic tools to detect 
myocarditis. 
CMR was first used in the 1990’s for detecting myocarditis, both with and without contrast-
agents, and several studies showed a high diagnostic accuracy for various combinations of 
CMR sequences (37). In 2009, a JACC white paper was published including expert advice 
for using CMR in diagnosing myocarditis (37). These recommendations were called the Lake 
Louise Consensus Criteria and stated that in cases where myocarditis is suspected clinically, 
CMR findings are consistent with inflammation if two of the following three criteria are 
fulfilled: i) signal enhancement on T2-weighted images, either regional or global (i e 
compared to skeletal muscle); ii) T1-weighted images showing an increased early gadolinium 
enhancement (EGE) ratio between myocardium and skeletal muscle; iii) late gadolinium 
enhancement images with one or more focal lesions with non-ischemic distribution (37). 
The second criteria, EGE ratio, is claimed to detect an increased distribution volume for the 
gadolinium contrast agent in the vessels and in the interstitium during the so called early 
washout phase (37). This enhancement was thought to represent hyperaemia and capillary 
leakage. However, this interpretation may be questionable given that a change in 
enhancement only can depend on a changes in the distribution volume (38), and this does not 
change markedly from early to late post-contrast (39). It was later found that the removal of 
the EGE ratio criterion did not change the overall accuracy for detecting myocarditis, 
although it lowered the sensitivity (40). 
Another problem raised in the white paper is that the EGE ratio, which is the ratio of early 
enhancement in the myocardium divided by the early enhancement in skeletal muscle, will be 
lower if myositis occurs at the same time (37). Furthermore, the EGE ratio has been shown to 
have the lowest area under the curve for identifying myocarditis compared to ECV, LGE, T2-
ratio as well as global T1 (41). 
For these reasons, we wanted to examine if there is a difference between early and late 
gadolinium enhancement ratios in Study I. To increase the measurement precision, this was 
performed using T1 mapping instead of T1-weighted images. Images from a representative 




Figure 5. Images from a representative patient with myocarditis. 
An example of a midventricular short-axis slice with a focal myocarditis lesion 
in the lateral myocardial wall (indicated by white arrows) in a representative 
patient with myocarditis. The images are: A) native (pre-contrast) T1 map (purple 
is normal and orange/yellow is high myocardial native T1), B) post-contrast T1 
map where the lesion is darker than other myocardium, indicating a lower T1 
which is due to a higher concentration of contrast agent, C) ECV map where the 
lesion is light blue, which indicates an ECV above 30 %, whereas the rest of the 
myocardium is blue/purple corresponding to the normal ECV range 20–30 %, D) 
Late gadolinium enhancement (LGE) image where the lesion has a high signal 
intensity and healthy myocardium is black. ECV = extracellular volume fraction; 
LGE = late gadolinium enhancement. 
Reproduction of figure and caption from Study I (42) licensed by John Wiley and Sons (License Number 
4814850078639). 
2.3 LEFT VENTRICULAR HYPERTROPHY 
Cardiovascular magnetic resonance (CMR) can be used to measure mass and the volumes of 
the left ventricle with excellent reproducibility (43). Left ventricular hypertrophy (LVH) is 
typically measured as an increased left ventricular mass (LVM) or LVM indexed (LVMi) to 
body surface area (BSA)  
LVH can be classified as concentric hypertrophy, where the left ventricular wall is thick but 
the volume is unchanged, or eccentric hypertrophy where the wall isn’t thick but the increase 
in mass is caused by enlargement of the heart, where the lateral enlargement makes it 
eccentric in regards to the normal position of the heart (44), hence the term eccentric 
hypertrophy. Concentric remodelling is defined as increased wall thickness but normal mass 
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(45). There is an increased risk for adverse events for both patients with concentric 
remodelling (45), and for patients with LVH (46). Images illustrating these types of 
hypertrophy and lack thereof are shown in Figure 6. 
 
Figure 6. Examples of hypertrophy, remodelling and normal configuration. 
The images show (clock-wise from bottom left corner): normal configuration 
with normal mass and wall thickness; concentric remodelling with high wall 
thickness but normal mass; concentric hypertrophy where both the wall thickness 
and the mass are high; and eccentric hypertrophy where the mass is high but the 
wall thickness is normal. 
Thickening walls and enlargement of the left ventricle does not need to be pathological. 
Athlete’s heart has been defined as enlargement of the heart due to physical activity (47). 
There are two types of athlete’s heart, one where volume loading from dynamic exercise, 
such as long distance running, can cause eccentric hypertrophy, and another where pressure 
loading from static exercise, such as weight lifting, can cause concentric hypertrophy (48). 
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Hypertrophic cardiomyopathy (HCM) is a genetic disorder which is characterised by an 
increase in LV wall thickness which affects either the whole LV or only a part of it in an 
asymmetric fashion. Also, patients with genetically verified HCM may not necessarily have 
an increased LV mass, since this may develop at a later age (49). 
Among sudden death in athletes in the United States of America, HCM accounts for more 
than one third of the confirmed cardiovascular causes (50). It is therefore important to be able 
to distinguish HCM from athlete’s heart in athletes (51). Patients with HCM usually have 
thickened walls but a ventricular septal thickness of 13–15 mm can both be caused by mild 
forms of HCM as well as by athlete’s heart (51). An algorithm for this intermediate state has 
therefore been developed, and it contains both left ventricular cavity size, left atrial 
enlargement, prominent ECG changes, as well as other findings (51). 
On echocardiography, classification of hypertrophy is based on the linear measure relative 
wall thickness (RWT), where the thickness of the left ventricular wall is measured in end 
diastole and divided by the end-diastolic diameter of the left ventricle. RWT can be 
calculated from the interventricular septal wall thickness at end diastole (IVSd) and/or the 
posterior wall thickness at end diastole (PWd), divided by the left ventricular end-diastolic 
dimension (LVEDD), as 2 ×	IVSd/LVEDD, or 2 ×	PWd/LVEDD, or (IVSD+PWd)/LVEDD. 
In patients with high LV mass, RWT is high in concentric hypertrophy and normal in 
eccentric hypertrophy, whereas patients with high RWT but normal mass are classified as 
having concentric remodelling (52). Sub-classification of LV remodelling has been proposed 
using a combination of volume, mass and relative wall thickness into as many as six 
categories (53). 
Another measure that can be used to characterise the left ventricle is concentricity0.67, which 
is calculated as LVM divided by LVEDV0.67 (54). The rationale for this measure is that the 
area (wall) of a sphere is calculated using the square of the radius whereas the volume of the 
sphere is calculated using the cube of the radius, taking LVEDV0.67 would thus give a ratio 
independent of the radius. Others have proposed using a combination of concentricity0.67, LV 
volume relative to BSA, and LVM relative to either height2.7 (54) or BSA (55). 
However, both relative wall thickness and mass-to-volume ratio have inherent 
methodological shortcomings where the former only measures the wall thickness in one 
location and none of them takes body size into account, and this may limit their diagnostic 
discriminatory ability. The use of three measures, such as concentricity0.67, mass and volume, 
also makes classification somewhat cumbersome and this could potentially be simplified.	
In Study III, we hypothesized 1) that it should be possible to estimate the global left 
ventricular end-diastolic mean wall thickness (GT) from CMR measures of LV mass and LV 
end-diastolic volume, 2) that the estimated GT could be used together with LV mass index to 
distinguish between different forms of hypertrophy, and 3) that survival could be used as an 





The specific aims of the four studies were: 
 
Study I: To use T1 mapping to determine whether there are any benefits of performing 
contrast enhanced imaging early or late post-contrast, with regards to detecting patients 
with acute myocarditis. 
 
Study II: To determine the prevalence of both diffusely increased ECV in remote 
myocardium and of focal LGE findings in a clinical population, and to explore how these 
findings relate to left ventricular size, mass, and systolic function. 
 
Study III: To derive and validate a new measure for global wall thickness that can be 
calculated from known parameters; to evaluate the prognostic performance of this new 
measure of wall thickness and other related measures; to use the most prognostic measure 
together with LV mass for classifying different types of hypertrophy; and finally to 
determine the outcomes for the same types of hypertrophy. 
 
Study IV: To develop and apply a clinical method for measuring the myocardial 
intracellular lifetime of water (τ) in patients with different types of left ventricular 





4 MATERIALS AND METHODS 
4.1 STUDY POPULATIONS 
All four studies contain patients from the database KAMRAT which was compiled for 
Study II. The patients were included in the database from September 2013 up until November 
2015 when 1000 patients had been included. 
These patients underwent CMR at 1.5 (Siemens Aera, Siemens Healthineers, Erlangen, 
Germany) at Karolinska University Hospital in Solna, Sweden. They were all referred for 
known or suspected disease involving the heart or the great vessels, and some were scanned 
as part of inclusion in other studies. 
4.1.1 Study I 
Patients were retrospectively identified from the KAMRAT database described above. The 
patients with myocarditis (n = 19) were diagnosed as having acute myocarditis by CMR. 
Acute presentation was defined as having a time between the start of the symptoms and the 
exam had being no more than four weeks. Since only one short-axis slice was imaged early 
post-contrast, both healthy and affected myocardium had to be identified in this slice. 
The controls (n = 19) were also identified from the KAMRAT database but had normal 
findings with normal ventricular volumes, normal systolic function, and no focal myocardial 
lesions or myocardial oedema. 
4.1.2 Study II 
This study was mainly based on the whole KAMRAT database but only included patients 
with clinical reports containing left ventricular volumes, mass and systolic function as well as 
measures of ECV and native T1 measured remotely from any focal lesions, and analysed LGE 
images. Since the main objective of Study II was to evaluate remote ECV, exclusion criteria 
were patients with amyloidosis since they are known to have areas of extremely high ECV, 
and hypertrophic cardiomyopathy, which is a unique genetic disorder. Only the first complete 
exam was included for patients with multiple exams. The final number of patients in the 
study was 609. 
Healthy volunteers (n = 38) were also included in order to establish the normal range for 
ECV. These subjects were originally included for another study (56), and these volunteers 
had no medical history of cardiovascular disease, kidney disease, or asthma, had no previous 
or current use of cardiovascular drugs, and none were current smokers. 
4.1.3 Study III 
This was a relatively large study with regards to number of patients, with a total of 2543 
subjects being included to address the various aims of the study. 
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4.1.3.1 Derivation and validation cohort 
The derivation and validation cohort was identified to derive and validate the new measure 
global wall thickness (GT). The cohort was made up of 537 test subjects and included healthy 
volunteers, endurance athletes, heart failure patients, patients with a recent myocardial 
infarction, and patients with unexplained chest pain, also known as cardiac syndrome X. 
The healthy volunteers were examined between 2001 and 2009, and included both young and 
old subjects who had no history of hypertension, or cardiovascular or systemic disease. The 
endurance athletes were competing in triathlon, football/soccer, handball, or swimming on an 
elite national level. They were scanned between 2005 and 2008. The patients with heart 
failure were candidates for implantation of a cardiac resynchronization therapy (CRT) 
pacemaker and underwent CMR between 2010 and 2014. The group of patients with 
myocardial infarction patients had an acute myocardial infarction and were included in 
several multicentre trials between 2011 and 2015. The patients with cardiac syndrome X 
underwent CMR between 2011 and 2016. 
All groups consisted of both males and females. This diverse group of patients were divided 
into a derivation cohort and a validation cohort, with an as equal as possible distribution of 
males and females from each diagnosis group in each cohort. 
4.1.3.2 Survival cohort 
The patients of the survival cohort (n = 1575) were consecutively included at the University 
of Pittsburgh Medical Center between 2010 and 2016. These patients have been studied 
previously with regards to prognostic outcome (57) but they have not been examined with 
regards to identifying and comparing various measures of left ventricular hypertrophy. 
Patients with amyloidosis were excluded since it is such a particular phenotype where an 
increased wall thickness can be caused by myocardial infiltration rather than cellular 
hypertrophy. 
4.1.3.3 Test-retest cohort 
To evaluate the repeatability of our new measure of wall thickness, a test-retest cohort 
(n = 101) was identified. This cohort included both healthy volunteers and patients with 
various pathologies. The subjects underwent CMR at various locations in the United 
Kingdom during 2010 to 2019. 
4.1.3.4 Mixed cohort 
In order to establish a range of normal values for the new wall thickness measures, the 
healthy volunteers from the derivation and validation cohort were supplemented with an 
additional 23 patients scanned in 2016, some of which were also included in Study II. This 
gave a total of 100 volunteers, but one of the female volunteers was found to have a highly 
abnormal global wall thickness index (GTi) that was four standard deviations above the mean 
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GTi for the other female volunteers. This case was removed since the test subject clearly was 
an outlier, and the final number of healthy volunteers was 99. 
To determine the performance of the new measures in additional patient groups, patients with 
a prominent left ventricular hypertrophy (n = 163) were included from the KAMRAT 
database and they all had a left ventricular mass index (LVMi) more than three standard 
deviations higher than the sex-specific mean, determined from the healthy volunteers above. 
Patients with Fabry disease (n = 144) were also included, they all had genetically confirmed 
disease and underwent CMR at The Heart Hospital (London, United Kingdom) between 2011 
and 2016. 
4.1.4 Study IV 
The patients for Study IV were retrospectively identified from the KAMRAT database, 
described previously. Four groups of patients with different combinations of LVMi and GTi, 
evaluated in terms of Z scores from the mean of healthy volunteers per sex, these were the 
same healthy volunteers used in Study III. The patients with concentric hypertrophy were 
identified by having the highest combination of LVMi and GTi in terms of the Z score for 
LVMi times the Z score of GTi divided by the sum of their Z scores; patients with eccentric 
hypertrophy had the highest Z scores for LVMi while still having a normal GTi; the patients 
with concentric remodelling on the other had the highest GTi but still having a normal LVMi; 
and the patients with normal configuration were as close to zero in terms of Z scores for both 
GTi and LVMi. 
Patients could only be included if they had overlapping midventricular short-axis T1 maps 
acquired before and at three time points post-contrast. Patients were excluded if: 1) there 
were artefacts, lesions or scars involving more than two segments (up to two segments could 
be excluded in the analysis), 2) the administered dose of contrast agent was lower than 0.15 
mmol/kg body weight, or 3) if the patient was diagnosed with Fabry disease or amyloidosis 
which both affect native T1. 
4.2 IMAGING AND ANALYSIS 
4.2.1 Study I 
It is important to clarify comparative measures comparing studies using different techniques 
such as signal intensities from T1-weighed images as opposed to magnetisation characteristics 
like T1. These are summarised in Table 1. The T1-weighted signal intensity (SI) used in the 
older studies corresponds to R1 (1/T1), and the signal enhancement (SE) which is calculated as 
(SIpost-contrast - SIpre-contrast)/SIpost-contrast corresponds to ∆R1/R1 pre-contrast. These enhancement 
measures correspond to Early gadolinium enhancement (EGE) when the post-contrast images 
are acquired early. Moreover, global relative enhancement (GRE = SEmyocardium / SEskeletal 
muscle) can be calculated from T1 maps as (∆R1 myocardium / R1 myocardium, pre-contrast)/(∆R1 skeletal muscle 
/ R1 skeletal muscle, pre-contrast).



















































































































































































































































































































































































































































































































































































































































































































































































































In the T1 maps of a midventricular short-axis slice, six regions of interest (ROIs) were placed 
in the midmural half of the left ventricular myocardial wall corresponding to segments 7 
through 12 in the 17-segment model of the left ventricle proposed by the American Heart 
Association (AHA) (58), see Figure 7. In order to be included, the patients had to have both 
affected and unaffected segments in the imaged short-axis slice. Segments were said to be 
affected either by having a native T1 above 1050 ms or if the mean native T1 of the affected 
segments was at least 50 ms higher than the mean native T1 of the unaffected segments in the 
same slice. 
 
Figure 7. A representative example of a midventricular short-axis native T1 
map. 
The left ventricular (LV) endocardium is outlined in red and the epicardium in 
green, with six blue regions of interest (ROIs) placed in the midmural 50 % of 
the myocardium. A blue ROI is placed in the LV blood pool and a white ROI is 
placed in the dorsal skeletal muscle. LV = left ventricular; ROI(s) = Region(s) of 
interest. 
Reproduction of figure and caption from Study I (42) licensed by John Wiley and Sons (License Number 
4814850078639). 
ROIs were also placed in the left ventricular blood pool and in dorsal skeletal muscle, see 
Figure 7. The ROIs were drawn on the native T1 maps and then copied to the post-contrast T1 
maps with small adjustments in position being made when necessary. 
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4.2.2 Study II 
The patients in Study II were analysed as a part of clinical routine using syngo.via (Siemens 
Healthineers, Erlangen, Germany) where the left ventricular endocardial and epicardial 
borders were outlined, with papillary muscles and trabeculations being included in the blood 
pool and not being included in the myocardium. The left ventricular volumes and mass were 
indexed to body surface area (BSA) calculated according to Mosteller (59). LGE images were 
examined for focal lesions and these were identified visually and reported when found. ECV 
and native T1 were measured in the corresponding short-axis maps, most often in the 
midmural part of the inferior section of the septum but always remotely from any scars or 
other focal abnormalities. 
The normal ranges for ECV were determined from healthy volunteers (n = 38, 50 % female) 
were ECV was measured in midventricular short-axis images in the midmural third of the 
septum. The upper limit was found to be 31 % for females and 30 % for males and these 
limits were used in the analysis of the patients. 
4.2.3 Study III 
All 2543 subjects of this study underwent CMR including steady state free precession (SSFP) 
cine imaging of the left ventricle. In the short-axis image stacks, the endocardial and 
epicardial borders were delineated in end systole and end diastole for measuring the left 
ventricular volumes and mass, where the mass excluded the papillary muscles and 
trabeculations were included in the blood pool. Volumes, mass, and other measures were 
index to body surface area (BSA) calculated using the Mosteller method (59). 
4.2.3.1 Derivation of validation of global wall thickness (GT) 
A new plug-in for the software Segment was developed in-house for purposes of measuring 
global wall thickness (GT) in order to validate the method for estimating GT. The plugin was 
used to measure GT from the test subjects’ cine images that had been analysed previously 
with the endocardial and epicardial borders stored. For every short-axis slice containing both 
blood pool and myocardium, the distance between the endocardial and epicardial borders was 
automatically measured at 24 equally spaced point along the circumference of each slice. 
Areas with a wall thickness of less than 2 mm were excluded since this constituted the 
outflow tract. The mean wall thickness of each slice was weighted to the mid-mural 
circumference of each slice in order to obtain the global wall thickness, representative of the 
whole left ventricle. A schematic illustration of the method for measuring GT is shown in the 
supplementary material for Study III, Figure S1. 
Geometrically, the wall thickness can only depend on the left ventricular mass and volume, 
and it should therefore be possible to calculate the wall thickness from these two measures. 
Mass and volume are always analysed in the clinical setting and a simple equation would 




GT = A + B • LVMX • LVEDVY   (Equation 7) 
where GT is mean global wall thickness, LVM is left ventricular mass, and LVEDV is left 
ventricular end-diastolic volume, and A, B, X, and Y are unknown constants that need to be 
determined. The derivation and validation cohort was split into a derivation cohort and a 
validation cohort with an as equal representation of diagnosis groups and sexes in the two 
cohorts. The mathematical software Matlab (R2016, Mathworks, Natick, Massachusetts, 
USA) was used to identify best fits for A, B, X and Y from Equation 7 by minimizing the sum 
of least squares to the measured wall thicknesses of the derivation cohort. 
4.2.3.2 Prognostic analysis 
For the prognostic analysis of the survival cohort, the time from the CMR exam to a 
composite end-point of death from all causes or hospitalisation for heart failure (HHF), which 
has been described previously (31). 
4.2.4 Study IV 
T1 mapping was performed using MOLLI 5(3)3 before contrast, as well as early and late post-
contrast, whereas a 4(1)3(1)2 MOLLI was used for the intermediate post-contrast imaging 
due to this being the clinical standard at the time. The patients received an intravenous bolus 
dose of a gadolinium-based contrast agent (gadoteric acid (Dotarem, Gothia Medical, Billdal, 
Sweden) 0.2 mmol/kg body weight) and the images were acquired early (median 
[interquartile range] 3.0 [2.5–4.0] minutes), intermediate (11 [8–13] minutes) and late (20 
[18–24] minutes) post-contrast. 
The analysis of the images in Study IV was similar to that of Study I with six regions of 
interest (ROIs) placed in the midmural half of the left ventricular myocardial wall. Similarly, 
an ROI was also placed in left ventricular blood pool in both T1 and T1* maps. The ROIs were 
drawn on the native T1 maps and copied to the post-contrast maps, again with small 
adjustments in position being made when necessary. If one or at most two segments were 
affected by artefacts or a focal lesion, these segments were excluded. 
A model for slow exchange transcytolemmal water exchange (60) was implemented in 
Matlab (R2018B, Mathworks, Natick, Massachusetts, USA). The Matlab code used to 
perform the calculations is included in the Appendix of the manuscript for this study. The 
model uses R1 (=1/T1) of the myocardium and of the blood, both before and at three time 
points post-contrast. A curve is fitted to these four points and the intracellular lifetime of 
water (τ) and ECV are obtained from the curve fitting. See Figure 17 for examples of R1 
curves. 
τ was calculated for all included segments of the myocardium and the resulting τ results were 
then averaged to yield the total average τ for the patient. ECV was calculated both using the 
model for slow exchange where all time points are used, and the commonly used fast 





5.1 STUDY I 
5.1.1 Affected versus remote segments 
In the patients with acute myocarditis (n = 19), native T1 was, by design, higher in affected 
compared to remote segments (median [inter-quartile range], 1090 [1071–1128] versus 1003 
[993–1020] ms, p < 0.001). The difference in native T1 between the affected and the remote 
segments was 83 [59–129] ms. The EGE equivalent measure was higher in affected versus 
remote segments both early and late, but the difference was higher late than early post-
contrast (34±5 % versus 30±4 %, p = 0.02). 
ECV was also higher in affected than in remote segments both early (27±1 % versus 23±1 %, 
p < 0.001) and late post-contrast (31±1 % versus 26±1 %, p < 0.001). The difference in ECV 
between affected and remote segments however was higher late than early post-contrast 
(5.3±0.7 % versus 4.0±0.6 %, p = 0.002), see Figure 8. 
 
Figure 8. Difference in apparent myocardial ECV between affected and 
remote segments.  
The difference in apparent myocardial ECV between affected and remote 
segments was higher late compared to early post-contrast in patients with 
myocarditis. The whiskers show the standard error of the mean. ECV = 
extracellular volume fraction. 




5.1.2 Myocarditis versus controls 
When comparing myocarditis patients to controls (n = 19), the GRE equivalent of the whole 
short-axis slice was higher in the myocarditis patients compared to controls both early post-
contrast (5.1 [4.5–6.5] versus 3.4 [2.5–4.5], p < 0.001) as well as late post-contrast (3.0 [2.6–
3.7] versus 2.0 [1.7–2.4], p < 0.001) as shown in Figure 9. Native T1 and ECV of skeletal 
muscle were both lower in the myocarditis patients compared to controls: 876 [843–915] ms 
versus 916 [896–939] ms, p = 0.02 for native T1 of skeletal muscle and both early post-
contrast ECV (5.1 [4.3–6.2] % versus 7.6 [5.7–9.0] %, p = 0.03) and late post-contrast 
ECV (10.2 [9.7–12.8] % versus 13.0 [11.4–15.7] %, p = 0.004), see Figure 9. 
 
Figure 9. The global relative enhancement equivalent and comparisons 
between dorsal skeletal muscle in myocarditis patients and in controls . 
The global relative enhancement (GRE) equivalent for the myocardium of the 
entire short-axis slice (center), including both remote and focally affected 
myocardium, was higher in myocarditis patients (grey boxes) than in controls 
(white boxes) both early and late post-contrast. The GRE equivalent in T1 
mapping is calculated as: (ΔR1myocardium/R1myocardium, pre-contrast) / (ΔR1skeletal muscle/R1 
skeletal muscle, pre-contrast). Both the native T1 of skeletal muscle (left) and the apparent 
ECV of skeletal muscle early and late post-contrast (right) was lower in 
myocarditis patients compared to controls. ECV = extracellular volume. The 
boxes show the interquartile range, the bar in the box shows the median and the 
whiskers show the range, except for outliers which are shown as circles or stars. 




5.1.3 Remote myocardium versus controls 
When comparing the remote myocardium of the myocarditis patients to the controls, the GRE 
equivalent was higher in the patients’ remote myocardium both early (5.0 [4.3–5.3] versus 3.4 
[2.5–4.5], p = 0.002) as well as late post- contrast (2.8 [2.4–3.1] versus 2.0 [1.7–2.4], 
p < 0.001). Native T1 was also higher in the myocarditis patients’ remote myocardium than in 
controls (1003 [993–1020] versus 996 [966–1007] ms, p = 0.03), but only to a small degree. 
Conversely, ECV did not differ between the remote myocardium of the myocarditis patients 
compared to the controls either early (22.7±0.9 % versus 21.7±0.4 %, p = 0.37) or late post-
contrast (25.8±0.7 % versus 25.2±0.5 %, p = 0.52), see Figure 10. 
 
Figure 10. Comparisons between remote myocardium in myocarditis 
patients and controls. 
The remote myocardium of the myocarditis patients (grey boxes) and the 
myocardium of the controls (white boxes) differed in GRE equivalent (left), and 
in native T1 (centre), but not in apparent myocardial ECV (right). ECV = 
extracellular volume. The box plot is used since the relative contrast 
concentration early post-contrast as well as myocardial native T1 in myocarditis 
patients did not follow a normal distribution; the Mann–Whitney U test was used 
for these two measures, and the unpaired t-test was used for the remaining 
measures. The boxes show the interquartile range, the bar in the box shows the 
median and the whiskers show the range, except for outliers which are shown as 
circles or stars. 




5.2 STUDY II 
Increased remote ECV was found in 50 out of 609 patients (8 %), 30 of these 50 the patients 
with increased ECV did not have focal LGE findings, see Figure 11. 
 
Figure 11. ECV and LGE findings. 
The limit for high ECV was set to remote ECV above 31 % for females and 
30 % for males. LGE+ indicates focal LGE findings and LGE- absence thereof. 
An increase in remote ECV was more common in patients with a pronounced LV dilatation 
(p < 0.001), in patients with a pronounced increase in LV mass index (LVMi) (p = 0.04) and 
in females (13.0 % versus 5.3 % in males, p < 0.001) whereas the prevalence of increased 
ECV did not differ in patients with or without a pronounced decrease in left ventricular 




Figure 12. Prevalence of diffusely increased ECV 
The figure shows the prevalence of diffusely increased ECV in patients with and 
without pronounced abnormalities in LVEF, LV dilatation, and LV mass 
respectively. LV=left ventricular; LVEF=left ventricular ejection fraction. 
Focal LGE on the other hand was more common patients with a pronounced decrease in 
LVEF (p < 0.001) but the prevalence in LGE did not differ for patients with or without 




Figure 13. Prevalence of focal LGE  
The figure shows the prevalence of focal LGE findings in patients with and 
without pronounced abnormalities in LVEF, LV dilatation, and LV mass 
respectively. LGE=late gadolinium enhancement; LV=left ventricular; 
LVEF=left ventricular ejection fraction. 
Similar results were obtained using logistic regression where a pronounced decrease in LVEF 
was associated with LGE (p < 0.001) but not with a high ECV (p = 0.41). On the other hand, 
pronounced LV dilation was associated with a high ECV (p = 0.001) but not with the 
presence of LGE (p = 0.054). 
The normal limits used for ECV were indirectly confirmed by examining patients with 
normal finding. The females with normal findings had a remote ECV of 27.0±2.0 % which 
corresponds to an upper limit of 31 % and the males had a remote ECV of 24.8±1.6 %, 
corresponding to an upper limit of 28 %. 
When used together, ECV mapping and native T1 mapping can be used to diagnose a wide 




Figure 14. Diagnostic diagram for native T1 and ECV. 
This diagram shows some examples of both global (blue) and focal (red) 
abnormalities that can be diagnosed using native T1 and/or ECV mapping. Please 
note that the limits for native T1 reflect conditions at 1.5 T and using our setup, 
that the upper limit for ECV for males is shown and that the upper limit for 
females was 1 %-point higher in our study.  
Adapted from Martin Ugander (SCMR 2014). 
5.3 STUDY III 
5.3.1 Calculating global wall thickness (GT) 
The fitting of the parameters of GT = A + B • LVMX • LVEDVY   (Equation 7) for calculating 
GT, to the measured wall thickness results of the derivation cohort resulted in the following 
equation: 
GT = 0.05 + 1.60 • LVM0.84 • LVEDV-0.49   (Equation 8) 
where GT is the global wall thickness measured in mm, LVM is mass of the left ventricular 
myocardium measured in grams, and LVEDV is left ventricular end-diastolic volume 
measured in millilitres. This equation (Equation 8) was then used for all other patients with 
no extra plug-in or application needed. The correlation between measured wall thickness and 
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calculated GT was found to be very high for both the derivation and the validation cohort, 
R2 = 0.95, p < 0.001 for both. There was no bias for the derivation cohort (0.00±0.24 mm) 
and very low bias for the validation cohort (0.01±0.23 mm), with low standard deviation for 
both cohorts. The standard deviation of the bias for the validation cohort implies a 95 % 
confidence interval if only 0.45 mm. 
5.3.2 Normal ranges for GT 
In the 99 healthy volunteers GT was found to be 5.9±0.6 mm and 7.2±0.7 mm for females 
and males, respectively, corresponding to normal ranges of 4.8–7.1 mm and 5.8–8.5 mm for 
females and males, respectively. 
In the healthy volunteers GT indexed (GTi) to body surface area (BSA) was found to be 
3.4±0.4 mm/m2 and 3.6±0.4 mm/m2 for females and males, respectively, which corresponds 
to normal ranges of 2.7–4.1 mm/m2 and 2.9–4.3 mm/m2 for females and males, respectively. 
For both sexes, both athletes and all patient groups had higher GT than the healthy volunteers 
(p < 0.02 for all groups separately for both sexes) with similar results for with GTi except for 
the CRT candidates which did not differ (p < 0.02 for both sexes for all groups except for 
CRT candidates). 
5.3.3 Test–retest 
The test-retest cohort (n = 101) was examined for test-retest variability for various measures 
and the variability was lowest for GT at 4.2 %. The highest variability was found for EDV 
and mass-to-volume ratio (6.1 % and 6.2 %, respectively, p < 0.001 for both versus GT). 
5.3.4 Prognostic analysis 
When analysing the whole survival cohort (n = 1575, 42 % female, follow-up time 5.4 [3.9–
6.4] years) by univariable Cox regression, it showed that the parameter with the highest 
prognostic value for hospitalisation for heart failure (HHF) or death, apart from age at CMR 
and presence of hypertension, was LVMi (χ2 66.7, p < 0.001) followed by GTi (χ2 37.3, 
p < 0.001) and GT (χ2 33.1, p < 0.001). In multivariable analysis including both LVMi and 
GTi, LVMi was associated with outcomes (p < 0.001) and GTi was not (p = 0.60). For more 
details, see Table 1 of Study IV. 
When analysing only the patients with normal findings for LVEDVi, LVMi, LVEF and no 
LGE (n = 326, 45 % female, follow-up time 5.8 [5.0–6.7] years) in the same way as above, 
the most prognostic parameters for the composite end-point HHF or death were GT (χ2 26.8, 
p < 0.001) and concentricity0.67 (χ2 26.6, p < 0.001), and these were more prognostic than 
both hypertension (χ2 23.5, p < 0.001) and age at CMR (χ2 14.5, p < 0.001). When 
multivariable analysis was performed including LVMi and GT, LVMi was not associated 
with outcomes (p = 0.70) but GT was (p = 0.01), see Table 2 of Study IV. 
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5.3.5 Classification by GTi and LVMi 
Patients of the mixed cohorts (who were not part of the prognostic cohort) were classified 
using GTi and LVMi, these numbers being indexed according to the mean and measured in 
standard deviations from the mean of the healthy volunteers per sex, see Figure 15. The 
patients with left ventricular hypertrophy were mostly classified as having concentric 
hypertrophy and patients with heart failure who were candidates for CRT implantation were 
mainly classified as having eccentric hypertrophy. Most endurance athletes were classified as 
normal but a fair amount as having eccentric hypertrophy. Although the median patient with 
Fabry disease was classified as having concentric hypertrophy, a large variability was seen 
both in terms of GTi and LVMi corresponding to the large variability of the disease. The 
healthy volunteers, the patients with normal findings, and the patients with acute myocardial 
infarction were all mainly classified as being normal. 
 
Figure 15. Characterisation of left ventricular hypertrophy using wall 
thickness and mass. 
The patient groups of the mixed cohort were classified according to their global 
wall thickness index (GTi) plotted against their left ventricular mass index 
(LVMi). The solid circles show the median and the whiskers show the 
interquartile range. Both GTi and LVMi were indexed to standard deviations 
(SD) from mean of the healthy volunteers per sex. The coloured fields show the 
proposed classification of hypertrophy based on LVMi and the new measure 
GTi. The grey dashed lines between the coloured fields indicate the upper limit 
of normal (+1.96 SD) for both measures. The mixed cohort consist of healthy 
volunteers, endurance athletes, cardiac resynchronization therapy (CRT) 
candidates, patients with recent acute ST-elevation myocardial infarction 
(Infarction), patients with Fabry disease (Fabry), and patients with at least 
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moderate left ventricular hypertrophy (LVH). Four examples of the proposed 
classification of hypertrophy are shown in the four corners. CMR, cardiovascular 
magnetic resonance; CRT, cardiac resynchronization therapy; LVH, left 
ventricular hypertrophy; LVMi, left ventricular mass index; SD, standard 
deviations; GTi, global wall thickness index. 
When the patients of the survival cohort (n = 1575), were classified using GTi and LVMi, the 
vast majority (78 %) were found to be normal, 6 % had concentric remodelling, 8 % had 
eccentric hypertrophy, and a similar number of 8 % had concentric hypertrophy. When 
comparing the four groups in terms of the composite end-point of death from all causes or 
HHF, the two groups of patients with hypertrophy did not differ (p = 0.77), and were 
therefore combined into a single hypertrophy group (16 % of all patients). This hypertrophy 
group had worse outcomes than both patients with concentric remodelling (p = 0.045), and 
patients classified as normal (p < 0.001). The patients with concentric remodelling also had a 
worse prognosis than the normal patients (p = 0.02). Kaplan-Meier curves for these three 
groups are shown below in Figure 16. 
 
Figure 16. Kaplan-Meier curves for the survival cohort. 
Kaplan-Meier curve for the patients of the survival cohort (n = 1575, follow-up 
time 5.4 [3.9–6.4] years) are shown with patients being classified as having 
either hypertrophy (increased LVMi regardless of GTi); concentric remodelling 
(normal LVMi, increased GTi); or being classified as normal (normal LVMi and 
GTi). The hypertrophic patients had a worse outcome compared to both the 
patients with concentric remodelling (p = 0.045) and the patients classified as 
being normal (p < 0.001). Patients with concentric remodelling also had worse 
prognosis compared to the normal group (p = 0.02). The limits for the GTi and 
LVMi were calculated from the healthy volunteers of the same study. CMR, 
cardiovascular magnetic resonance; GTi, global wall thickness indexed to body 
surface area; LVMi, left ventricular mass indexed to body surface area. 
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5.4 STUDY IV 
A total of 63 patients were included in the study and the intracellular lifetime of water (τ) was 
found to be (median [interquartile range]) 78 [30–108] ms for normal patients (n = 17); 69 
[13–107] ms for patients with concentric hypertrophy (n = 18); 73 [50–91]ms for patients 
with eccentric hypertrophy (n = 14), and 99 [63–175] ms for patients with concentric 
remodelling (n = 14). When comparing the results of the four groups, τ was found to be 
higher in patients with concentric remodelling than in patients with eccentric hypertrophy 
(p = 0.03), whereas no other group differed from any another group (p > 0.05), see Figure 3 
of Study IV. Nine patients of the 63 (14 %) had a τ below 5 ms. Examples of two patients 
with very different τ are shown below in Figure 17. 
  
Figure 17. Examples of R1 curves. 
Examples of two patients with eccentric remodelling with R1 in myocardium 
plotted versus R1 in blood with the lowest R1 values pre-contrast and the highest 
early post-contrast. The black line indicates the fast exchange (FX) model (Left: 
ECVFX 28 %, Right: ECVFX 27 %); the black dots show the results per 
myocardial segment; and the red curve shows the mean of the curve-fittings per 
segment for the slow exchange (SX) model, (Left: ECVSX 32 %, τ 111 ms, 
Right: ECVSX 27 %, τ 30 ms). 
The slow exchange (SX) model used for calculating τ yielded higher ECV in all four groups 
compared to the commonly used fast exchange (FX) model (p < 0.01 for all groups), see 







Study I: When detecting myocarditis using T1 mapping, there was no clear benefit of 
performing early instead of late post-contrast imaging. 
 
Study II: In this clinical population of 609 patients, 50 (8 %) had diffusely increased 
extracellular volume fraction that was not detected by other imaging techniques and 30 
(60 %) of these patients did not have any focal findings. LV size was independently 
associated with increased ECV, whereas systolic dysfunction was independently 
associated with LGE. 
 
Study III: Left ventricular mass indexed to body mass was the most prognostic measure 
for all-cause mortality and hospitalisation for heart failure in a large clinical population of 
1575 patients. In the subset of patients with normal findings by cardiovascular magnetic 
resonance imaging who numbered 326, the new measure of global wall thickness (GT) 
was the most prognostic. This suggests that a combination of left ventricular mass and GT 
are the optimal measures for classifying left ventricular hypertrophy. 
 
Study IV: Indirect measurement of cardiomyocyte size by contrast-enhanced 
cardiovascular magnetic resonance imaging is not reliable in a clinical setting with the 






7.1 DETECTING MYOCARDITIS BY CMR 
Study I (42) found no benefit of performing early post-contrast imaging (early gadolinium 
enhancement) when detecting acute myocarditis. On the other hand, focal abnormalities were 
more prominent late post-contrast as indicated by the greater difference in ECV between 
affected and unaffected segments at that time point, see Figure 8. 
The early gadolinium enhancement (EGE) ratio was included in the so called Lake Louise 
criteria published in 2009 (37) and the EGE criterion was based upon four earlier studies 
(36,61–63). Since mapping techniques were not available at the time, T1-weighted imaging 
was used. These images can show focal abnormalities well, but since they cannot detect 
abnormalities that affect the whole myocardium, skeletal muscle was chosen as a reference 
tissue. 
An obvious problem with this method is that skeletal muscle can also be affected by a general 
inflammation. Indeed, this study found difference between skeletal muscle in myocarditis 
patients and in controls, see Figure 9. However, native T1 and ECV of skeletal muscle was 
not higher in myocarditis patients as could be expected, rather, it was lower. The reasons for 
these findings are unclear but possible explanations could be dehydration or other unknown 
factors. Nevertheless, this illustrates the problem of using skeletal muscle as a reference 
tissue for myocardial imaging. By comparison, T1 and ECV mapping provide measures in 
absolute units of measure. 
When comparing remote myocardium in myocarditis patients to the healthy myocardium of 
controls we found that ECV did not differ either early or late post-contrast; that native T1 was 
higher, but only slightly higher, in the remote myocardium in myocarditis patients compared 
to controls; and that global relative enhancement was higher in the remote myocardium of 
myocarditis patients compared to controls both early and late post-contrast. Since global 
relative enhancement uses skeletal muscle as a reference, these findings could be explained 
by the difference in skeletal muscle discussed above. 
The original Lake Louise criteria (37) were updated in 2018 and no longer contain explicit 
recommendations for using EGE (64). The criteria now instead include oedema detected by 
T2 weighted imaging or T2 mapping, as well as abnormalities identified on either native T1 
maps, ECV maps or LGE images (64). Where the old criteria (37) stated that regional 
vasodilation in the myocardium caused enhancement early post-contrast, our findings do not 
support this theory, but rather indicate that enhancement is caused by an extracellular 
expansion and that the contrast agent is rapidly distributed in all extracellular space and does 
not give greater contrast enhancement early compared to late post-contrast. Although the 
2018 criteria (37) do not include EGE, they do, however, mention early enhancement as a 
target for imaging when detecting myocarditis, and that it is unclear whether this is caused by 
hyperaemia or an extracellular expansion, where our findings suggest the latter. 
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7.2 PREVALENCE OF INCREASED ECV 
The main finding of Study II was that 8 % of patients, in a clinical population consisting of 
patients with known or suspected heart disease, hade diffusely increased ECV in remote 
myocardium. Out of these patients, 60 % (5 % of all patients) had increased ECV without any 
focal findings. These patients represent a non-negligible part of all patients and an increased 
ECV, measured in myocardium that is free from focal LGE. Such ECV measurements have 
been found to be associated with adverse events including elevated mortality, and 
hospitalisation for cardiac reasons (27–31,57). These patients are important to identify at an 
early stage to provide the best possible treatment in order to mitigate adverse outcomes. 
ECV in healthy volunteers was higher in females than in males, and female sex was also the 
strongest predictor of remote ECV in multivariate analysis. A previous study also found 
higher ECV in females than in males, but since ECV in males increased with age, the 
differences between the sexes disappeared for older patients (65). Different limits for females 
and males thus seem to be warranted, and perhaps also different limits for different age 
groups. 
Increased ECV was more common in patients that had a pronounced dilatation of the left 
ventricle compared to patients without such dilatation. Previous studies have also shown that 
patients with dilated cardiomyopathy had higher ECV compared to controls (66–68). It has 
also been shown that ECV correlates well with the amount of collagen found in biopsy 
samples of these patients (66). There therefore seems to be a clear connection between diffuse 
myocardial fibrosis and dilatation, but the cause-effect relationship between the two remains 
unclear. By comparison, there was no difference in the prevalence of increased remote ECV 
in patients with or without a pronounced decrease in left ventricular systolic function. 
In contrast, focal LGE findings were more common in patients with a pronounced decrease in 
left ventricular systolic function. Similarly, previous studies have found an inverse 
relationship between infarct size and left ventricular ejection faction in patients with 
myocardial infarction (69,70). These findings seem reasonable since focal lesions represent 
areas that do not contribute to the systolic function. However, the prevalence of focal LGE 
did not differ between patients with or without a pronounced dilatation. 
7.3 GLOBAL WALL THICKNESS 
The main finding of Study III, that a measure of the global mean wall thickness (GT) can be 
easily calculated from the end-diastolic volume (EDV) and mass of the left ventricle is 
arguably the most novel finding in this thesis. 
In a large clinical cohort, left ventricular mass indexed (LVMi) to body surface area (BSA) 
was the most prognostic measure for the composite endpoint of all-cause mortality and 
hospitalisation for heart failure (HHF). The second most prognostic measure among all 
patients was GT indexed (GTi) to BSA. In the patients with normal findings, GT was more 
prognostic than all other measures, including both hypertension and age. GT (and therefore 
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GTi) also had a test-retest repeatability that was better than that for both LVM and EDV. In 
contrast to direct measurements of the wall thickness using either CMR or echocardiography, 
GT is less prone to sampling error and reflects the average wall thickness of the whole heart. 
Previously proposed methods for characterising left ventricular hypertrophy have used 
measures including mass-to-volume ratio (71) and concentricity0.67 (54,72). These measures 
are not immediately intuitive, and the latter methods also requires both concentricity0.67, LV 
mass and LVEDV for characterizing hypertrophy. The method proposed in Study IV uses two 
measures, LVMi and GTi, which are both relatively intuitive. 
Taken together, it seems reasonable to use GTi together with LVMi for characterising 
different forms of hypertrophy, as illustrated in Figure 15. When applying this methodology 
to the survival cohort, it was somewhat surprisingly found that there were no differences in 
adverse outcomes between eccentric and concentric hypertrophy, and these patients were 
therefore examined as one group. This lack of differences in outcomes between eccentric and 
concentric hypertrophy may have been in part related to a relatively smaller sample size for 
these subgroups. The combined hypertrophy group had a worse outcome compared to 
patients with concentric remodelling which in turn had worse outcomes than patients with 
normal mass and thickness. 
The principle drawback of GT is that the EDV and LVM have to be determined by including 
papillary muscles and major trabeculations in the blood pool. For other ways of analysing 
EDV and LVM, a new equation for GT would need to be derived and verified. 
7.4 MEASURING CARDIOMYOCYTE SIZE NON-INVASIVELY 
The results from Study IV showed no difference in τ between different hypertrophy subgroups 
and controls despite defining the groups so as to maximise the chances of finding differences. 
That as many as 14 % the patients had intracellular lifetime of water (τ) values that were 
lower than 5 ms, which is not physiologically reasonable, indicates that the method is not 
robust and reliable enough to work for humans in a clinical setting despite working in mice. 
Although mice and humans show many differences, myocyte size (15) and extracellular 
space, which is close to 25 % for both mice (9) and humans (16), are not among those 
differences. The dose of contrast agent in the previous work was 0.5 mmol/kg body weight 
(73,74) which is 2.5 times more than the of 0.2 mmol/kg of body weight was used for 
Study IV. A higher contrast dose would entail lower T1 values and consequently higher R1 
values giving more certainty in curve-fitting. However, higher doses than 0.2 mmol/kg of 
body weigh are not recommended in humans. In the previous studies in mice, the contrast 
agent was also administered subcutaneously with step-wise increases. In Study IV, on the 
other hand, the contrast agent was administered intravenously as a bolus dose, and 
measurements were made for slowly decreasing rather than step-wise increasing contrast 
agent concentrations. This difference, as well as the lower dose of contrast agent, could have 
contributed to the results. A non-invasive method for measuring the size of the myocytes 
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could possibly be useful for diagnosing various heart diseases, including hypertrophy, and 
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